AstraZeneca Urges Court to Find Seroquel Claims Preempted

ORLANDO, Fla. - Seroquel manufacturer AstraZeneca has asked a federal judge to dismiss as preempted the failure-to-warn claims of several plaintiffs who allege they developed diabetes as a result of taking the antipsychotic after the FDA approved a label that included stronger warnings about the disease. In Re: Seroquel Products Liability Litigation, MDL No. 1769 (M.D. Fla.).

In a motion for judgment on the pleadings filed July 31, AstraZeneca contends that the claims of 11 plaintiffs with cases pending in the federal Seroquel MDL are barred under the doctrine of implied conflict preemption. The drug maker says that the plaintiffs …